Crossmark

Therapeutic silencing of mTOR by systemically administered siRNA-loaded neutral liposomal nanoparticles inhibits DMBA-induced mammary carcinogenesis

Published Online: 2022-10-19

Published Print: 2022-12-07

Authors

Sahu, Roja

Jha, Shivesh

Pattanayak, Shakti Prasad https://orcid.org/0000-0002-1629-2648
Funding

Funding for this research was provided by:

University Grants Commission (201819-NFO-2018-19-OBC-ORI-80495)
License Information

Text and Data Mining valid from 2022-10-19

Version of Record valid from 2022-10-19
More Information

Article History

Received: 5 June 2022

Revised: 28 September 2022

Accepted: 4 October 2022

First Online: 19 October 2022

Competing interests

: The authors declare no competing interests.

: This animal study was approved by the Institutional Animal Ethical Committee, Birla Institute of Technology, Mesra, Ranchi (approval no. 1972/PH/BIT/113/20/IAEC). All animal experiments were conducted in accordance with the Institutional Animal Ethical Committee (IAEC) regulation. This study did not include patient participation or analysis of patient data.

Document is current